skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Review of tipranavir in the treatment of drug-resistant HIV

(1941) Views  (355) Full article downloads

Authors: Hendrik Streeck, Jürgen Kurt Rockstroh

Published Date October 2007 Volume 2007:3(4) Pages 641 - 651
DOI: http://dx.doi.org/10.2147/TCRM.S

Hendrik Streeck, Jürgen Kurt Rockstroh

Department of Medicine I, University of Bonn, Bonn, Germany

Abstract: Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of patients with HIV. Low adherence and toxicity among HIV-positive patients starting HAART, however, can lead to discontinuation of therapy and limit long-term treatment success. Moreover, increasing prevalence of primary resistance (>10%) as well as the accumulation of mutations resulting from continued selection pressure exerted by ongoing antiretroviral treatment in patients failing virologically, mean that new compounds are needed that retain antiretroviral activity against resistant strains. Tipranavir (Aptivus®) is a novel protease inhibitor (NPPI), which is characterized by a unique genetic resistance profile that allows it to remain active against HIV strains resistant to currently licensed protease inhibitors (PIs). Tipranavir was approved and licensed in the US and Europe in 2005 for treatment-experienced patients. This review summarizes the currently available data and studies on tipranavir and discusses the possible position of tipranavir in the currently available armamentarium of antiretroviral drugs.

Keywords: tipranavir, resistance, salvage, AIDS








Readers of this article also read:

Prevention of shingles: safety and efficacy of live zoster vaccine
Clinical studies with oral lipid based formulations of poorly soluble compounds
Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol
Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results
Ondansetron oral disintegrating tablets for the prevention of postoperative vomiting in children undergoing strabismus surgery
Using risk management files to identify and address causative factors associated with adverse events in pediatrics
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study
Controversial data on simvastatin in asthma: What about the rat model?
The spectrum of use of rituximab in chronic lymphocytic leukemia